Phenylephrine Hydrochloride Solution/ Drops
NDC Package 68083-593-01
Package Information
Phenylephrine Hydrochloride solution/ dropses is phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, is indicated to dilate the pupil. This formulation utilizes a solution/ drops delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-593 and is authorized under FDA application ANDA218129.
Identification & Billing
- RxCUI: 1234571 - phenylephrine HCl 10 % Ophthalmic Solution
- RxCUI: 1234571 - phenylephrine hydrochloride 100 MG/ML Ophthalmic Solution
- RxCUI: 1234571 - phenylephrine hydrochloride 10 % Ophthalmic Solution
- RxCUI: 1234579 - phenylephrine HCl 2.5 % Ophthalmic Solution
- RxCUI: 1234579 - phenylephrine hydrochloride 25 MG/ML Ophthalmic Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68083 - Gland Pharma Limited
- 68083-593 - Phenylephrine Hydrochloride
- 68083-593-01 - 1 BOTTLE, DROPPER in 1 CARTON / 2 mL in 1 BOTTLE, DROPPER
- 68083-593 - Phenylephrine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68083-593-01 identifies a specific commercial package of 1 bottle, dropper in 1 carton / 2 ml in 1 bottle, dropper of Phenylephrine Hydrochloride, a human prescription drug labeled by Gland Pharma Limited. This solution/ drops is formulated for ophthalmic use and contains phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on December 18, 2024. The current certification is valid through December 31, 2026.
How is this Gland Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083059301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.